Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

Section 4 - Therapeutic aspects: prevention, future directions, and possibilities

References

1. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010;341:3666.
2. Altmann-Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011;42:638–644.
3. Fields WS, Lemak NA. A History of Stroke. Its Recognition and Treatment. New York, NY: Oxford University Press; 1989.
4. Hauw JJ. The history of lacunes. In Donnan G, Norrving B, Bamford J, Bogousslavsky J, eds. Subcortical Stroke, 2nd edn. New York, NY: Oxford University Press; 2002: pp. 3–15.
5. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774–784.
6. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–876.
7. Lammie GA, Brannan F, Slattery J, Warlow C. Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke 1997;28:2222–2229.
8. Potter GM, Doubal FN, Jackson CA, et al. Counting cavitating lacunes underestimates the burden of lacunar infarction. Stroke 2010;41:267–272.
9. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke 2005;36:891–901.
10. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2007;78:702–706.
11. Boiten J, Lodder J, Kessels F. Two clinically distinct lacunar infarct entities? A hypothesis. Stroke 1993;24:652–656.
12. Arauz A, Murillo L, Cantu C, Barinagarrementeria F, Higuera J. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases. Stroke 2003;34:2453–2458.
13. Nah HW, Kang DW, Kwon SU, Kim JS. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010;41:2822–2827.
14. Longstreth WT, Jr., Bernick C, Manolio TA, et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217–1225.
15. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
16. Van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: the Rotterdam Scan Study. Stroke 2008;39:2712–2719.
17. Gouw AA, van der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new lacunes over a three-year period: the Leukoaraiosis And DISability study. Stroke 2008;39:1414–1420.
18. Jackson CA, Hutchison A, Dennis MS, et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. Stroke 2009;40:3679–3684.
19. Cheung N, Liew G, Lindley RI, et al. Retinal fractals and acute lacunar stroke. Ann Neurol 2010;68:107–111.
20. Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010;41:450–454.
21. Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012;78:1043–1050.
22. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, et al. Endothelial activation in lacunar stroke subtypes. Stroke 2010;41:1617–1622.
23. Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012;78:167–174.
24. Van Dijk EJ, Prins ND, Vermeer SE, et al. Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 2004;55:570–575.
25. Babikian V, Ropper AH. Binswanger’s disease: a review. Stroke 1987;18:2–12.
26. McQuinn BA, O’Leary DH. White matter lucencies on computed tomography, subacute arteriosclerotic encephalopathy (Binswanger’s disease), and blood pressure. Stroke 1987;18:900–905.
27. Sulkava R, Erkinjuntti T. Vascular dementia due to cardiac arrhythmias and systemic hypotension. Acta Neurol Scand 1987;76:123–128.
28. Pantoni L, Inzitari D, Pracucci G, et al. Cerebrospinal fluid proteins in patients with leucoaraiosis: possible abnormalities in blood–brain barrier function. J Neurol Sci 1993;115:125–131.
29. Moody DM, Brown WR, Challa VR, Anderson RL. Periventricular venous collagenosis: association with leukoaraiosis. Radiology 1995;194:469–476.
30. Liao D, Cooper L, Cai J, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC study. Neuroepidemiology 1997;16:149–162.
31. Longstreth WT, Jr., Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274–1282.
32. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004;35:1857–1861.
33. De Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002;125(Pt 4):765–772.
34. Dufouil C, de Kersaint-Gilly A, Besancon V, et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI cohort. Neurology 2001;56:921–926.
35. Van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004;44:625–630.
36. Bakker SL, de Leeuw FE, de Groot JC, et al. Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999;52:578–583.
37. Mok V, Xiong Y, Wong KK, et al. Predictors for cognitive decline in patients with confluent white matter hyperintensities. Alzheimers Dement 2012;8(Suppl 5):S96–S103.
38. Brickman AM, Reitz C, Luchsinger JA, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 2010;67:564–569.
39. Goldstein IB, Bartzokis G, Hance DB, Shapiro D. Relationship between blood pressure and subcortical lesions in healthy elderly people. Stroke 1998;29:765–772.
40. Ylikoski A, Erkinjuntti T, Raininko R, et al. White matter hyperintensities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 1995;26:1171–1177.
41. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann Neurol 2002;51:285–289.
42. Hassan A, Hunt BJ, O’Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127(Pt 1):212–219.
43. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull 1999;55:669–682.
44. De Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 2009;80:149–157.
45. De Lau LM, Refsum H, Smith AD, Johnston C, Breteler MM. Plasma folate concentration and cognitive performance: the Rotterdam Scan Study. Am J Clin Nutr 2007;86:728–734.
46. Longstreth WT, Jr., Katz R, Olson J, et al. Plasma total homocysteine levels and cranial magnetic resonance imaging findings in elderly persons: the Cardiovascular Health Study. Arch Neurol 2004;61:67–72.
47. Vuorinen M, Solomon A, Rovio S, et al. Changes in vascular risk factors from midlife to late life and white matter lesions: a 20-year follow-up study. Dement Geriatr Cogn Disord 2011;31:119–125.
48. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors and brain morphology in identical older male twins. Neurology 1999;52:1119–1124.
49. Schmidt R, Hayn M, Fazekas F, Kapeller P, Esterbauer H. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 1996;27:2043–2047.
50. Jimenez-Conde J, Biffi A, Rahman R, et al. Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 2010;41:437–442.
51. Xu H, Stamova B, Jickling G, et al. Distinctive RNA expression profiles in blood associated with white matter hyperintensities in brain. Stroke 2010;41:2744–2749.
52. Simpson JE, Hosny O, Wharton SB, et al. Microarray RNA expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways. Stroke 2009;40:369–375.
53. Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928–939.
54. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: six-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046–2048.
55. Markus HS, Hunt B, Palmer K, et al. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005;36:1410–1414.
56. Longstreth WT, Jr., Arnold AM, Beauchamp NJ, Jr., et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36:56–61.
57. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)–Dijon Magnetic Resonance Imaging Study. Circulation 2011;123:266–273.
58. Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk In Communities (ARIC) study. Stroke 2010;41:3–8.
59. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection aGainst Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation 2005;112:1644–1650.
60. Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. J Neurol 2009;256:750–757.
61. Cavalieri M, Schmidt R, Chen C, et al. B vitamins and MRI-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012;43:3266–3270.
62. Van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005;112:900–905.
63. Schmidt R, Schmidt H, Pichler M, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006;37:2910–2916.
64. Kase CS. Subcortical hemorrhages. In Donnan G, Norrving B, Bamford J, Bogousslavsky J, eds. Subcortical Stroke, 2nd edn. New York, NY: Oxford University Press; 2002: pp. 347–377.
65. Caplan LR. Hypertensive intracerebral hemorrhage. In Kase CS, Caplan LR, eds. Intracerebral Hemorrhage. Boston, MA: Butterworth–Heinemann; 1994: pp. 99–116.
66. Wolf PA. Epidemiology of intracerebral hemorrhage. In Kase CS, Caplan LR, eds. Intracerebral Hemorrhage. Boston, MA: Butterworth–Heinemann; 1994: pp. 21–30.
67. Grysiewicz R, Gorelick PB. Update on amyloid-associated intracerebral hemorrhage. Eur Neurol Rev 2012;7:22–24.
68. Gorelick PB. Statin use and intracerebral hemorrhage: evidence for safety in recurrent stroke prevention? Arch Neurol 2012;69:13–16.
69. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011;124:2233–2242.
70. Folsom AR, Yatsuya H, Mosley TH, Jr., Psaty BM, Longstreth WT, Jr. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol 2012;71:552–559.
71. Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012;71:199–205.
72. Weng YC, Sonni A, Labelle-Dumais C, et al. COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012;71:470–477.
73. Cole FM, Yates PO. Comparative incidence of cerebrovascular lesions in normotensive and hypertensive patients. Neurology 1968;18:255–259.
74. Offenbacher H, Fazekas F, Schmidt R, et al. MR of cerebral abnormalities concomitant with primary intracerebral hematomas. AJNR Am J Neuroradiol 1996;17:573–578.
75. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–642.
76. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007;130:1988–2003.
77. Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke 2010;41(Suppl 10):S103–S106.
78. Staals J, van Oostenbrugge RJ, Knottnerus IL, et al. Brain microbleeds relate to higher ambulatory blood pressure levels in first-ever lacunar stroke patients. Stroke 2009;40:3264–3268.
79. Lee SH, Bae HJ, Yoon BW, et al. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 2002;33:2845–2849.
80. Wieberdink RG, Poels MM, Vernooij MW, et al. Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2011;31:2982–2989.
81. Haussen DC, Henninger N, Kumar S, Selim M. Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. Stroke 2012;43:2677–2681.
82. Day JS, Policeni BA, Smoker WR, et al. Previous statin use is not associated with an increased prevalence or degree of gradient-echo lesions in patients with acute ischemic stroke or transient ischemic attack. Stroke 2011;42:354–358.
83. Ovbiagele B, Liebeskind DS, Pineda S, Saver JL. Strong independent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack. Arch Neurol 2010;67:45–50.
84. Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: systematic review and meta-analyses. Neurology 2011;77:158–167.
85. Gregoire SM, Brown MM, Kallis C, et al. MRI detection of new microbleeds in patients with ischemic stroke: five-year cohort follow-up study. Stroke 2010;41:184–186.
86. Poels MM, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011;42:656–661.
87. Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010;74:1954–1960.

References

1. Petty GW, Brown RD, Jr., Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062–1068.
2. O’Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
3. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.
4. Mok VC, Lau AY, Wong A, et al. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. Int J Stroke 2009;4:81–88.
5. Sacco RL, Kargman DE, Zamanillo MC. Race–ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: the Northern Manhattan Stroke Study. Neurology 1995;45:659–663.
6. Samanci N, Dora B, Kizilay F, et al. Factors affecting one year mortality and functional outcome after first ever ischemic stroke in the region of Antalya, Turkey (a hospital-based study). Acta Neurol Belg 2004;104:154–160.
7. Soda T, Nakayasu H, Maeda M, et al. Stroke recurrence within the first year following cerebral infarction – Tottori University Lacunar Infarction Prognosis Study (TULIPS). Acta Neurol Scand 2004;110:343–349.
8. Worley KL, Lalonde DR, Kerr DR, Benavente O, Hart RG. Survey of the causes of stroke among Mexican Americans in South Texas. Tex Med 1998;94:62–67.
9. Yokota C, Minematsu K, Hasegawa Y, Yamaguchi T. Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis 2004;18:111–116.
10. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–876.
11. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002;12:358–370.
12. Feekes JA, Hsu SW, Chaloupka JC, Cassell MD. Tertiary microvascular territories define lacunar infarcts in the basal ganglia. Ann Neurol 2005;58:18–30.
13. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774–784.
14. Fisher CM. The arterial lesions underlying lacunes. Acta Neuropathol 1968;12:1–15.
15. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.
16. Benavente OR, White CL, Pearce L, et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011;6:164–175.
17. Clavier I, Hommel M, Besson G, Noelle B, Perret JE. Long-term prognosis of symptomatic lacunar infarcts. A hospital-based study. Stroke 1994;25:2005–2009.
18. Nadeau SE, Jordan JE, Mishra SK, Haerer AF. Stroke rates in patients with lacunar and large vessel cerebral infarctions. J Neurol Sci 1993;114:128–137.
19. Gandolfo C, Moretti C, Dall’Agata D, et al. Long-term prognosis of patients with lacunar syndromes. Acta Neurol Scand 1986;74:224–229.
20. Hier DB, Foulkes MA, Swiontoniowski M, et al. Stroke recurrence within two years after ischemic infarction. Stroke 1991;22:155–161.
21. Miyao S, Takano A, Teramoto J, Takahashi A. Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke 1992;23:1434–1438.
22. Landi G, Cella E, Boccardi E, Musicco M. Lacunar versus non-lacunar infarcts: pathogenetic and prognostic differences. J Neurol Neurosurg Psych 1992;55:441–445.
23. Brainin M, Seiser A, Czvitkovits B, Pauly E. Stroke subtype is an age-independent predictor of first-year survival. Neuroepidemiology 1992;11:190–195.
24. Boiten J, Lodder J. Prognosis for survival, handicap and recurrence of stroke in lacunar and superficial infarction. Cerebrovasc Dis 1993;3:221–226.
25. Samuelsson M, Lindell D, Norrving B. Presumed pathogenetic mechanisms of recurrent stroke after lacunar infarction. Cerebrovasc Dis 1996;6:128–136.
26. Salgado AV, Ferro JM, Gouveia-Oliveira A. Long-term prognosis of first-ever lacunar strokes. A hospital-based study. Stroke 1996;27:661–666.
27. Yamamoto Y, Akiguchi I, Oiwa K, Hayashi M, Kimura J. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke 1998;29:570–576.
28. Staaf G, Lindgren A, Norrving B. Pure motor stroke from presumed lacunar infarct: long-term prognosis for survival and risk of recurrent stroke. Stroke 2001;32:2592–2596.
29. Eriksson SE, Olsson JE. Survival and recurrent strokes in patients with different subtypes of stroke: a 14-year follow-up study. Cerebrovasc Dis 2001;12:171–180.
30. Kazui S, Levi CR, Jones EF, et al. Lacunar stroke: transoesophageal echocardiographic factors influencing long-term prognosis. Cerebrovasc Dis 2001;12:325–330.
31. Yamamoto Y, Akiguchi I, Oiwa K, et al. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. Stroke 2002;33:297–305.
32. De Jong G, van Raak L, Kessels F, Lodder J. Stroke subtype and mortality. A follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262–268.
33. Jackson CA, Hutchison A, Dennis MS, et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. Stroke 2009;40:3679–3684.
34. Suto Y, Kowa H, Nakayasu H, et al. Relationship between three-year survival and functional outcome at discharge from acute-care hospitals in each subtype of first-ever ischemic stroke patients. Intern Med 2011;50:1377–1383.
35. Stead LG, Gilmore RM, Bellolio MF, et al. Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat 2011;2011:281496.
36. Kwan MW, Mak W, Cheung RT, Ho SL. Ischemic stroke related to intracranial branch atheromatous disease and comparison with large and small artery diseases. J Neurological Sci 2011;303:80–84.
37. Ntaios G, Michel P. Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype. Cerebrovasc Dis 2011;32:246–253.
38. Melkas S, Putaala J, Oksala NK, et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology 2011;76:734–739.
39. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
40. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O’Fallon WM. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;22:1236–1241.
41. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–634.
42. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG. Predicting survival for one year among different subtypes of stroke. Results from the Perth Community Stroke Study. Stroke 1994;25:1935–1944.
43. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–2740.
44. Hata J, Tanizaki Y, Kiyohara Y, et al. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psych 2005;76:368–372.
45. Bejot Y, Catteau A, Caillier M, et al. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke 2008;39:1945–1951.
46. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl J Med 2001;345:1444–1451.
47. Sacco RL, Prabhakaran S, Thompson JL, et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin–Aspirin Recurrent Stroke study. Cerebrovasc Dis 2006;22:4–12.
48. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
49. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006;355:549–559.
50. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New Engl J Med 2008;359:1238–1251.
51. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for Prevention of Secondary Stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–968.
52. Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New Engl J Med 2012;367:817–825.
53. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol 2003;2:238–245.
54. Jackson C, Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005;128(Pt 11):2507–2517.
55. Norrving B. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol 2008;8:222–228.
56. Jacova C, Pearce LA, Costello R, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol 2012;72:351–362.
57. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947.
58. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995;333:1581–1587.
59. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71–75.
60. Cocho D, Belvis R, Marti-Fabregas J, et al. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol 2006;55:70–73.
61. Fluri F, Hatz F, Rutgers MP, et al. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol 2010;17:1054–1060.
62. Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011;42:102–106.
63. Ohara T, Nagakane Y, Tanaka E, et al. Clinical and radiological features of stroke patients with poor outcomes who do not receive intravenous thrombolysis because of mild symptoms. Eur Neurol 2012;69:4–7.
64. Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines–Stroke. Stroke 2011;42:3110–3115.
65. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463–2466.
66. Palumbo V, Boulanger JM, Hill MD, Inzitari D, Buchan AM. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007;68:1020–1024.
67. Demchuk AM, Khan F, Hill MD, et al. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA stroke study. Cerebrovasc Dis 2008;26:120–125.
68. Shoamanesh A, Kwok CS, Lim PA, Benavente OR. Postthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysis. Int J Stroke 2013;8:348–356.
69. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004;14:54–57.
70. Del Bene A, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012;7:321–329.
71. Donnan GA, Bladin PF, Berkovic SF, Longley WA, Saling MM. The stroke syndrome of striatocapsular infarction. Brain 1991;114(Pt 1A):51–70.
72. Donnan GA, O’Malley HM, Quang L, Hurley S, Bladin PF. The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993;43:957–962.
73. Paul NL, Simoni M, Chandratheva A, Rothwell PM. Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012;79:1356–1362.
74. Kennedy J, Hill MD, Ryckborst KJ, et al. Fast Assessment of Stroke and Transient ischaemic attack to prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–969.
75. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New Engl J Med 2013;369:11–19.
76. Khan A, Kasner SE, Lynn MJ, Chimowitz MI. Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke 2012;43:1230–1233.
77. Bailey EL, Smith C, Sudlow CL, Wardlaw JM. Pathology of lacunar ischemic stroke in humans – a systematic review. Brain Pathol 2012;22:583–591.
78. Bousser MG, Eschwege E, Haguenau M, et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5–14.
79. Gent M, Blakely JA, Easton JD, et al. The Canadian–American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.
80. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
81. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol Stroke Prevention Study: a placebo-controlled doubleblind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–157.
82. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947–2957.
83. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–1673.
84. Bousser MG, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013–2022.
85. Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the Cilostazol Stroke Prevention Study. Cerebrovasc Dis 2008;26:63–70.
86. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461–2469.
87. Makkar RR, Eigler NL, Kaul S, et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19:1538–1546.
88. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502.
89. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227–276.
90. Ebrahim S, Sung J, Song YM, et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean National Health System Prospective Cohort Study. BMJ 2006;333:22.
91. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. New Engl J Med 1989;320:904–910.
92. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
93. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–463.
94. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405–1409.
95. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70(24 Pt 2):2364–2370.
96. O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–123.
97. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet 1990;336:370–371.
98. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.
99. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
100. PROGRESS Management Committee. PROGRESS – The Perindopril Protection aGainst Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999;17:1647–1655.
101. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28:2557–2562.
102. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–2748.
103. Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–515.
104. Jackson CA, Hutchison A, Dennis MS, et al. Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy? Stroke 2010;41:624–629.
105. Micheli S, Agnelli G, Palmerini F, et al. Need for extensive diagnostic work-up for patients with lacunar stroke. J Neurol 2008;255:637–642.
106. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHADS2–VASc and HAS–BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemostasis 2013;110:1074–1079.
107. Rajapakse A, Rajapakse S, Sharma JC. Is investigating for carotid artery disease warranted in non-cortical lacunar infarction? Stroke 2011;42:217–220.
108. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP. Severe ipsilateral carotid stenosis and middle cerebral artery disease in lacunar ischaemic stroke: innocent bystanders? J Neurol 2002;249:266–271.
109. Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnett HJ. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000;54:660–666.
110. Barnett HJ, Meldrum HE, Eliasziw M. The appropriate use of carotid endarterectomy. CMAJ 2002;166:1169–1179.

References

1. US Food and Drug Administration. New drug, antibiotic, and biological drug product regulations; accelerated approval–FDA. Final rule. Fed Regist 1992;57:58942–58960.
2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605–613.
3. Schmidt R, Scheltens P, Erkinjuntti T, et al. White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004;63:139–144.
4. Fazekas F, Niederkorn K, Schmidt R, et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. Stroke 1988;19:1285–1288.
5. De Leeuw F-E, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002;125:765–772.
6. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004;35:1857–1861.
7. Gottesman RF, Coresh J, Catellier DJ, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk In Communities (ARIC) study. Stroke 2010;41:3–8.
8. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683–1689.
9. Chimowitz MI, Estes ML, Furlan AJ, Awad IA. Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol 1992;49:747–752.
10. Scarpelli M, Salvolini U, Diamanti L, et al. MRI and pathological examination of postmortem brains: the problem of white matter high signal areas. Neuroradiology 1994;36:393–398.
11. Scheltens P, Barkhof F, Leys D, et al. Histopathologic correlates of white matter changes on MRI in Alzheimer’s disease and normal aging. Neurology 1995;45:883–888.
12. Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful aging, a five-year follow-up study from the eighth to ninth decade of life. Magn Reson Imaging 1996;14:601–608.
13. Veldink JH, Scheltens P, Jonker C, Launer LJ. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998;51:319–320.
14. Whitman GT, Tang Y, Lin A, Baloh RW, Tang T. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 2001;57:990–994.
15. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F. Progression of cerebral white matter lesions: six-year results of the Austrian Stroke Prevention Study. Lancet 2003;361:2046–2048.
16. Taylor WD, MacFall JR, Provenzale JM, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol 2003;181:571–576.
17. Garde E, Lykke Mortensen E, Rostrup E, Paulson OB. Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neurol Neurosurg Psychiatr 2005;76:1289–1291.
18. Ten Dam VH, van den Heuvel DMJ, van Buchem MA, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005;64:1807–1809.
19. Gouw AA, van der Flier WM, Fazekas F, et al. Progression of white matter hyperintensities and incidence of new lacunes over a three-year period: the Leukoaraiosis And DISability Study. Stroke 2008;39:1414–1420.
20. Van Dijk EJ, Prins ND, Vrooman HA, et al. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: the Rotterdam Scan Study. Stroke 2008;39:2712–2719.
21. Maillard P, Crivello F, Dufouil C, et al. Longitudinal follow-up of individual white matter hyperintensities in a large cohort of elderly. Neuroradiology 2009;51:209–220.
22. Longstreth WT, Arnold AM, Beauchamp NJ, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36:56–61.
23. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over three years. Neurology 2007;68:214–222.
24. Lo RY, Jagust WJ. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012;79:1349–1355.
25. Maillard P, Carmichael O, Fletcher E, et al. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 2012;79:442–448.
26. Van den Heuvel DMJ, ten Dam VH, de Craen AJM, et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatr 2006;77:149–153.
27. Holtmannspötter M, Peters N, Opherk C, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: a two-year follow-up study. Stroke 2005;36:2559–2565.
28. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000;356:628–634.
29. Kramer JH, Mungas D, Reed BR, et al. Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology 2007;21:412–418.
30. Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008;71:108–113.
31. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 2005;58:610–616.
32. Firbank MJ, Teodorczuk A, van der Flier WM, et al. Relationship between progression of brain white matter changes and late-life depression: three-year results from the LADIS study. Br J Psychiatr 2012;201:40–45.
33. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008;65:94–100.
34. Van Straaten ECW, Harvey D, Scheltens P, et al. Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008;255:1302–1308.
35. Inzitari D, Pracucci G, Poggesi A, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (Leukoaraiosis And DISability) Study Cohort. BMJ 2009;339:2477.
36. Prins ND, van Straaten ECW, van Dijk EJ, et al. Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004;62:1533–1539.
37. Schmidt R, Berghold A, Jokinen H, et al. White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. Stroke 2012;43:2643–2647.
38. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke 2007;38:2619–2625.
39. Ferris SH. General measures of cognition. Int Psychogeriatr 2003;15(Suppl 1):215–217.
40. Longstreth WT, Bernick C, Manolio TA, et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217–1225.
41. Arauz A, Murillo L, Cantú C, Barinagarrementeria F, Higuera J. Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases. Stroke 2003;34:2453–2458.
42. Giroud M, Milan C, Beuriat P, et al. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks. The Stroke Registry of Dijon: 1985–1989. Int J Epidemiol 1991;20:892–899.
43. Longstreth WT, Dulberg C, Manolio TA, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002;33:2376–2382.
44. Gouw AA, van der Flier WM, Pantoni L, et al. On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke 2008;39:3083–3085.
45. Jokinen H, Gouw AA, Madureira S, et al. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011;76:1872–1878.
46. Jeerakathil T, Wolf PA, Beiser A, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004;35:1831–1835.
47. Vernooij, MW van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds. Neurology 2008;70:1208–1214.
48. Loitfelder M, Seiler S, Schwingenschuh P, Schmidt R. Cerebral microbleeds: a review. Panminerva Medica 2012;54:149–160.
49. Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999;20:637–642.
50. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537–539.
51. Poels MMF, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam Scan Study. Stroke 2010;41:103–106.
52. Poels MMF, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011;42:656–661.
53. Lee S-H, Lee S-T, Kim BJ, et al. Dynamic temporal change of cerebral microbleeds: long-term follow-up MRI study. PloS One 2011;6:e25930.
54. Liem MK, Haan J, Neut IL, et al. MRI correlates of cognitive decline in CADASIL. Neurology 2009;72:143–148.
55. Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer’s disease: postmortem quantitative MRI and neuropathology. Brain 2008;131:3286–3298.
56. Holland PR, Bastin ME, Jansen MA, et al. MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler 2004;10:182–187.
57. Schmierer K, Altmann DR, Kassim N, et al. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Mult Scler 2004;10:182–187.
58. Shereen A, Nemkul N, Yang D, et al. Ex vivo diffusion tensor imaging and neuropathological correlation in a murine model of hypoxia–ischemia-induced thrombotic stroke. J Cerebral Blood Flow Metab 2011;31:1155–1169.
59. Holland PR, Bastin ME, Jansen MA, et al. MRI is a sensitive marker of subtle white matter pathology in hypoperfused mice. Neurobiol Aging 2011;32:2325.
60. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56:407–415.
61. Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008;39:1999–2005.
62. Jokinen H, Schmidt R, Ropele S, et al. Diffusion changes predict cognitive and functional outcome. The LADIS study. Ann Neurol 2013;73:576–583.
63. Hong YJ, Yoon B, Lim S-C, et al. Microstructural changes in the hippocampus and posterior cingulate in mild cognitive impairment and Alzheimer’s disease: a diffusion tensor imaging study. Neurological Sci 2013;34:1215–1221.
64. Teipel SJ, Meindl T, Wagner M, et al. Longitudinal changes in fiber tract integrity in healthy aging and mild cognitive impairment: a DTI follow-up study. J Alzheimer’s Dis 2010;22:507–522.
65. Chua TC, Wen W, Slavin MJ, Sachdev PS. Diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease: a review. Curr Opin Neurol 2008;21:83–92.
66. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection aGainst Recurrent Stroke Study) magnetic resonance imaging substudy. Circulation 2005;112:1644–1650.
67. Cavalieri M, Schmidt R, Chen C, et al. B vitamins and MRI-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke 2012;43:3266–3270.
68. Fornage M, Debette S, Bis JC, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol 2011;69:928–939.

References

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.
2. Stephens RB, Stilwell DL. Arteries and Veins of the Human Brain. Springfield, IL: Charles C Thomas; 1969: pp. 3–42.
3. Garcia LH, Ho K-H, Pantoni L. Pathology. In Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke. Pathophysiology, Diagnosis, and Management, 3rd edn. New York, NY: Churchill Livingstone; 1998: pp. 139–158.
4. Lammie GA. Pathology of lacunar infarction. In Donnan G, Norrving B, Bamford J, Bogousslavsky J, eds. Subcortical Stroke, 2nd edn. Oxford: Oxford University Press; 2002: pp. 37–46.
5. Ward NS, Brown MM. Leukoaraiosis. In Donnan G, Norrving B, Bamford J, Bogousslavsky J, eds. Subcortical Stroke, 2nd edn. Oxford: Oxford University Press; 2002: pp. 47–66.
6. Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment. Evidence from clinicopathological studies in humans. Stroke 2012;43:2526–2534.
7. Simpson JE, Hosny O, Wharton SB, et al. Microarray RNA expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways. Stroke 2009;40:369–375.
8. Hachinski V. World Stroke Day 2008. “Little strokes, big trouble.” Stroke 2008;39:2407–2408.
9. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–2713.
10. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to aging and neurodegeneration: a unified approach. Standards for ReportIng Vascular changes on nEuroimaging (STRIVE). Lancet Neurol 2013;12:822–838.
11. Lancet Neurology Editorial. Towards a European Brain–Health Union. Lancet Neurology 2013;12:525.
12. Freiderich MJ. Dementia should be a priority. JAMA 2012;307:2017.
13.World Health Organization and Alzheimer’s Disease International. Dementia: A Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed June 9, 2013).
14. NINDS Stroke Progress Review Group. Report from the Stroke Research Priorities Meeting: Top Scientific Research Opportunities from Workgroups on Stroke Prevention, Treatment, and Recovery Research. http://www.ninds.nih.gov/find_people/ninds/OSPP/stroke-priorities-2012.pdf (accessed January 2, 2014).
15. Hachinski V, Donnan GA, Gorelick PB, et al. Stroke: working toward a prioritized world agenda. Stroke 2010;41:1084–99.
16.Canadian Best Practice Recommendations for Stroke Care. Mood and Cognition, 4th edn. http://www.strokebestpractices.ca/index.php/cognition-mood/ (accessed June 19, 2013).